Influential cancer group rolls out first set of 'affordability' ratings on cancer drugs

The National Comprehensive Cancer Network unveiled its first set of "evidence blocks" that include cost information on oncology drugs; this first round focuses on chronic myelogenous leukemia (CML) and multiple myeloma. Drugs from Bristol-Myers Squibb ($BMY), Novartis ($NVS), Johnson & Johnson ($JNJ), and Celgene ($CELG), among others, were assessed on efficacy, safety and affordability. More from FiercePharmaMarketing

Suggested Articles

The company will commit $300 million over the next five years to hire more people of color and increase clinical trial diversity.

Moderna, after tapping almost $1 billion in federal funding, agreed to deliver 100 million doses of its vaccine candidate for up to $1.5 billion.

FDA advisors will question the clinical data and manufacturing for Mesoblast's Ryoncil, a cell therapy for pediatric acute graft vs. host disease.